Anthracin 50mg Inj 1 S

What it is used for: Cancer.

Indications as listed by the manufacturer: Epirubicin is administered for the treatment of: - Breast cancer; - Stomach cancer; - Epirubicin hydrochloride is also used intravesically (directly into the bladder) to treat early (superficial) urinary bladder cancer and to help prevent recurrence of bladder cancer after surgery.

How it works: The mechanism of action of Epirubicin Hydrochloride is related to its ability to bind to DNA. Cell culture studies have shown rapid cell penetration, localisation in the nucleus and inhibition of nucleic acid synthesis and mitosis. Pharmorubicin has proved to be active on a wide spectrum of experimental tumours including L1210 and P388 leukaemias, sarcomas SA180 (solid and ascitic forms), B16 melanoma, mammary carcinoma, Lewis lung carcinoma and colon carcinoma . It has also shown activity against human tumours transplanted into athymic nude mice (melanoma, mammary lung, prostatic and ovarian carcinomas).

Active ingredient: Epirubicin Hydrochloride.

Reported side effects: Decrease in the production of blood cells (bone marrow depression; resulting in a shortage of white blood cells, red blood cells, platelets), which involves an increased sensitivity to infections and anaemia. - Hair loss (alopecia, in 60-90% of treated cases. It involves poor beard growth in men. Hair loss is dose-dependent and in most cases reversible) - Red coloration of urine for 1 to 2 days after administration , Infection , Hot flashes , loss of appetite (anorexia), dehydration , Mucous membrane inflammation (mucositis; can occur 5 to 10 days after the start of the treatment), inflammation of the mucous membrane of the oesophagus (esophagitis) or mouth (stomatitis), vomiting, diarrhea which can result in dehydration, nausea (nausea and vomiting often occur within the first 24 hours (in nearly all patients)) - Redness at infusion site .

Known drug interactions: Cimetidine , Paclitaxel and docetaxel , Calcium channel blockers , Interferon alfa-2b , Quinine , Antibiotics such as sulphonamide and chloramphenicol. - Antiretroviral , Diphenylhydantoin , Painkillers such as amidopyrin derivatives , Dexrazoxane , Dexverapamil .

Carcinoma of the lung When used as a single agent at high doses in the treatment of pulmonary carcinoma, Epirubicin should be administered according to the following regimens: small cell lung cancer in previously untreated patients: 120 mg/m² on day 1, every three weeks. Non small cell lung cancer (epidermoid, squamous and adenocarcinoma) in previously untreated patients: 135 mg/m² on day 1 or 45 mg/m² on Days 1,2,3, every three weeks. Carcinoma of the breast : Doses of up to 135 mg/m², when used as the sole agent, and up to 120 mg/m² when used in combination therapy, administered every 3-4 weeks, have been found to be effective and well tolerated in patients suffering from carcinoma of the breast. OR As directed by your physician.

Active ingredient: Epirubicin Hydrochloride. Labelled strength: 50mg.

Store in a refrigerator (2°C–8°C). Do not Freeze .

Manufactured by Anthracin Pharmaceuticals (Pvt) Ltd.. Country of origin: Turkey.